(Food and Drug Safety Administration
[Provided by Yonhap News TV])
(Seoul = Yonhap News) Reporter Yoo Han-joo = The Food and Drug Safety Administration announced on the 23rd that in order to strengthen the safety management of pharmaceuticals, biopharmaceuticals, herbal medicines, quasi-drugs, and medical devices, they will conduct the “2025 Second Quarter Joint Planned Inspection by Medical Product Sector” in cooperation with regional food and drug safety departments and local governments by the 27th.
For pharmaceuticals, they will inspect manufacturers with a history of product recall due to packaging or labeling defects. The main inspection points include whether follow-up actions and recurrence prevention measures, submitted by the company during the drug recall, have been implemented.
In the biopharmaceutical sector, there will be a focus on managing glucagon-like peptide-1 (GLP-1) weight management drugs.
They will monitor whether unauthorized information has been exaggeratedly or falsely advertised to the public by medical institutions and pharmacies handling these products.
For herbal medicines, given the need for quality control of high-priced herbal ingredients, they will inspect manufacturing establishments of herbal ingredients such as deer antler and cattle-derived gallstones, as well as manufacturers of herbal formulations containing these, such as Woohwangcheongsimwon.
For quasi-drugs, the focus will be on ensuring a safe distribution environment for anti-snoring devices, inspecting whether manufacturers are conducting quality inspections of raw materials and finished products.
Regarding medical devices, they will inspect companies that have frequently been caught bringing in illegal medical devices during import and customs stages. The primary inspection will focus on the illegal distribution of illegally imported medical devices.
The Ministry of Food and Drug Safety stated, “We will continue to conduct regular inspections on medical products to ensure public safety.”